BTG2 and BTG1 were considered as anti-proliferation genes and frequently deleted or mutated in hematological malignancies with aggressive cell behavior and treatment resistance (27). TET2 mutations impaired enhancer H3K27 acetylation and disrupted transit of B cells through germinal centers, leading to lymphomagenesis (28). This evidence concerns the gene BTG1 and hematologic disorder.